Biotechnology Assets Sa Stock Fundamentals
| BST Stock | 0.34 0.01 3.03% |
Biotechnology Assets SA fundamentals help investors to digest information that contributes to Biotechnology Assets' financial success or failures. It also enables traders to predict the movement of Biotechnology Stock. The fundamental analysis module provides a way to measure Biotechnology Assets' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotechnology Assets stock.
Biotechnology |
Biotechnology Assets SA Company Operating Margin Analysis
Biotechnology Assets' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Biotechnology Assets Operating Margin | (0.63) % |
Most of Biotechnology Assets' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotechnology Assets SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Biotechnology Assets SA has an Operating Margin of -0.6322%. This is 98.2% lower than that of the Healthcare sector and 99.44% lower than that of the Biotechnology industry. The operating margin for all Spain stocks is 88.53% lower than that of the firm.
Biotechnology Assets Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotechnology Assets's current stock value. Our valuation model uses many indicators to compare Biotechnology Assets value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotechnology Assets competition to find correlations between indicators driving Biotechnology Assets's intrinsic value. More Info.Biotechnology Assets SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biotechnology Assets by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biotechnology Assets' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Biotechnology Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotechnology Assets' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotechnology Assets could also be used in its relative valuation, which is a method of valuing Biotechnology Assets by comparing valuation metrics of similar companies.Biotechnology Assets is currently under evaluation in operating margin category among its peers.
Biotechnology Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.0647 | |||
| Profit Margin | (0.92) % | |||
| Operating Margin | (0.63) % | |||
| Shares Outstanding | 48.35 M | |||
| Shares Owned By Insiders | 51.21 % | |||
| Revenue | 3.28 M | |||
| Gross Profit | 3.01 M | |||
| EBITDA | (1.04 M) | |||
| Book Value Per Share | 0.1 X | |||
| Number Of Employees | 33 | |||
| Beta | 1.51 | |||
| Market Capitalization | 13.64 M | |||
| Annual Yield | 0.53 % |
About Biotechnology Assets Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotechnology Assets SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Assets using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Assets SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biotechnology Stock
Biotechnology Assets financial ratios help investors to determine whether Biotechnology Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Assets security.